Phase 1 IND approval in Korea for our innovative Alzheimer's therapeutic, AS-S603

Exciting Milestone Achieved! We are thrilled to announce that Amyloid Solution has received Phase 1 IND approval in Korea for our innovative Alzheimer's therapeutic, AS-S603! This achievement marks a significant step forward in our mission to combat Alzheimer’s disease and bring hope to patients worldwide. "Title: A randomized, double-blind, placebo-controlled, single- and multiple-oral administration, phase 1 clinical trial to investigate the safety, tolerability, and pharmacokinetics of AS-S603 in healthy Korean or Caucasian adults and Korean elderly people" https://lnkd.in/e9bq8bTX A big thank you to our dedicated team who made this possible. We look forward to advancing AS-S603 through clinical development and sharing more updates soon. LIST ADDRESS. #601, C's Tower, 58, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea TEL. +82-31-8092-3800 FAX. +82-31-8092-3801 EMAIL. General : [email protected] Business : [email protected] Careers : [email protected] (C) 2020. Amyloid Solution Inc. All rights reserved Privacy Policy

The release as fetched from its publisher. amyloidsolution.com ↗